Tel Aviv, Israel – ICL Israel Chemicals (NYSE: ICL) released its financial results for the third quarter, reporting earnings per share (EPS) of $0.110, surpassing the analyst consensus by $0.01, which had estimated EPS at $0.098. However, revenue for the same quarter amounted to $1.86 billion, falling short of the consensus estimate of $1.89 billion.
As a result of this financial update, ICL Israel Chemicals’ stock price concluded at $4.810. The company’s stock performance reveals a decline of -26.000% over the last three months and a more significant decrease of -40.910% over the past year.
Over the last 90 days, ICL Israel Chemicals witnessed 0 positive EPS revisions and 2 negative EPS revisions, indicative of the changing sentiment surrounding the company’s earnings. Interested individuals can explore the stock price’s historical responses to previous earnings reports for further insights.
InvestingPro has assigned ICL Israel Chemicals a “great performance” rating for its financial health, affirming the company’s stability and robustness in the current economic landscape.
For more comprehensive information regarding ICL Israel Chemicals’ recent earnings performance and financials, please refer to their official reports.
To stay informed about upcoming earnings reports, please consult earnings calendar, ensuring you remain up-to-date with the latest financial updates and market developments.